| 陈 群,赵艳芳,王砚青,徐 彧,杨 洋.阿托伐他汀联合替格瑞洛对冠心病不稳定型心绞痛患者炎性因子、血脂及不良心脏事件的影响[J].,2020,(11):2080-2083 |
| 阿托伐他汀联合替格瑞洛对冠心病不稳定型心绞痛患者炎性因子、血脂及不良心脏事件的影响 |
| Effects of Atorvastatin Combined with Tegrilol on Inflammatory Factors, Blood Lipids and Adverse Cardiac Events in Patients with Unstable Angina Pectoris of Coronary Heart Disease |
| 投稿时间：2019-10-28 修订日期：2019-11-23 |
| DOI：10.13241/j.cnki.pmb.2020.11.016 |
| 中文关键词: 阿托伐他汀 替格瑞洛 冠心病不稳定型心绞痛 炎性因子 不良心脏事件 血脂 |
| 英文关键词: Atorvastatin Tegrilol Unstable angina pectoris of coronary heart disease Inflammatory factors Adverse cardiac events Lipid |
| 基金项目:南京军区医学科技创新项目（14ZD22） |
|
| 摘要点击次数: 760 |
| 全文下载次数: 380 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀联合替格瑞洛对冠心病不稳定型心绞痛（UAP）患者炎性因子、血脂及不良心脏事件的影响。方法：选取2016年2月~2019年2月期间我院收治的103例冠心病伴UAP患者，采用乱数表法将其分为研究组（n=52）和对照组（n=51），对照组给予阿托伐他汀联合氯吡格雷治疗，研究组给予阿托伐他汀联合替格瑞洛治疗，比较两组临床疗效、炎性因子、血脂、心绞痛发作情况及不良心脏事件。结果：研究组治疗1个月后的临床疗效为88.46%（46/52），高于对照组的66.67%（34/51）（P<0.05）。两组治疗1个月后总胆固醇（TC）、超敏-C反应蛋白（hs-CRP）、三酰甘油（TG）、白介素-6（IL-6）、低密度脂蛋白胆固醇（LDL-C）、心绞痛发作次数、肿瘤坏死因子-α（TNF-α）、心绞痛持续时间均降低，而高密度脂蛋白胆固醇（HDL-C）升高（P<0.05），研究组治疗1个月后TC、TG、LDL-C、IL-6、hs-CRP、TNF-α、心绞痛发作次数、心绞痛持续时间低于对照组，而HDL-C则高于对照组（P<0.05）。两组不良心脏事件发生率比较差异无统计学意义（P>0.05）。结论：阿托伐他汀联合替格瑞洛治疗冠心病伴UAP患者，疗效确切，可有效改善其炎性因子、血脂水平，且不增加不良心脏事件发生率，临床应用价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Atorvastatin Combined with tegrilol on inflammatory factors, blood lipids and adverse cardiac events in patients with unstable angina pectoris(UAP). Methods: 103 patients with coronary heart disease and UAP who were admitted to our hospital from February 2016 to February 2019 were selected, they were randomly divided into study group (n=52), control group(n=51). The control group was treated with Atorvastatin Combined with clopidogrel, and the study group was treated with Atorvastatin Combined with clopidogrel. The clinical efficacy, inflammatory factors, blood lipids, angina pectoris and adverse cardiac events were compared between the two groups. Results: The clinical efficacy of the study group was 88.46% (46/52) after one month of treatment, which was higher than 66.67% (34/51) of the control group (P<0.05). One month after treatment, total cholesterol (TC), hypersensitive C-reactive protein (hs-CRP), triglyceride (TG), interleukin-6 (IL-6), low density lipoprotein cholesterol (LDL-C), frequency of angina attack, tumor necrosis factor-α (TNF-α) and duration of angina pectoris in both groups decreased, while high density lipoprotein cholesterol(HDL-C) decreased. The TC, TG, LDL-C, IL-6, hs-CRP, TNF-α, angina attack times and duration of angina in the study group were lower than those in the control group one month after treatment, while HDL-C was higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse cardiac events between the two groups (P>0.05). Conclusion: Atorvastatin combined with Tiglillo is effective in the treatment of UAP patients with coronary heart disease. It can effectively improve the levels of inflammatory factors and blood lipids without increasing the incidence of adverse cardiac events, and has high clinical value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
